Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM) in a report released on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

NASDAQ PULM opened at $6.72 on Monday. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $8.44. The stock has a 50 day moving average of $2.34 and a 200-day moving average of $2.13.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.